BTK Inhibitors
6 drugsAbout BTK
Bruton's tyrosine kinase (BTK) is a tyrosine kinase enzyme crucial for cell signaling pathways in immune cell development and function. As a non-receptor tyrosine kinase, BTK is essential for B-cell receptor signaling and downstream activation of pathways. Its role in immune cell function makes it a valuable target for therapeutic intervention.
Human genetic studies provide strong validation for BTK as a therapeutic target, with a max genetic score of 0.95. Loss-of-function variants are associated with X-linked agammaglobulinemia (score 0.95) and isolated growth hormone deficiency (score 0.94), suggesting activation of BTK may be beneficial.
BTK is targeted by five FDA-approved small molecule drugs, including IMBRUVICA, CALQUENCE and JAYPIRCA. These drugs are used in oncology (2 drugs) and other therapeutic areas (3 drugs). Approvals span from IMBRUVICA in 2013 to RHAPSIDO in 2025.
BTK Genetic Evidence Strong
BTK has strong genetic support with a maximum score of 0.95 linked to X-linked agammaglobulinemia.
Strong genetic support suggests that therapies activating BTK have a higher probability of clinical success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 2 traits
- • Strong signal in nervous system disease, endocrine system disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
8 totalGWAS and other genetic studies link BTK to 8 diseases.
Loss-of-function causes disease; activation may help
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top BTK Drugs
Five companies have approved BTK-targeting drugs, including PHARMACYCLICS LLC, AstraZeneca and Novartis.
The presence of multiple companies suggests a competitive market, but also established pathways for regulatory approval.
BTK Drug Modality Landscape
Modalities
Routes of Administration
BTK is amenable to small molecule drugs, with oral options available for convenient dosing.
The exclusive use of small molecules indicates a potential whitespace opportunity for alternative modalities like antibodies.
BTK Clinical Trials 533 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on BTK. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 185 | 99 | 35 | 51 | 74% |
| Phase 2 | 252 | 75 | 34 | 143 | 69% |
| Phase 3 | 86 | 25 | 4 | 57 | 86% |
| Phase 4 | 10 | 3 | 0 | 7 | 100% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved BTK drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting BTK. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
BTK Drug Approval Timeline (2013 - 2025)
BTK has seen approvals spanning 13 years, from 2013 to 2025.
The recent approval of RHAPSIDO in 2025 indicates continued interest and potential for further drug development targeting BTK.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 6 companies competing
- • Market share by company
Full Drug Portfolio
- • All 6 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 6-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 167 (42 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on BTK. A trial counts if an approved drug acting on BTK is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.